LUPIN-LETERMOVIR DIN 02559331
Health Canada record
| Active ingredient(s) | LETERMOVIR 480 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J05AX18 LETERMOVIR |
| Original market date | 03-Jun-2026 |
| Current status date | 03-Jun-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Lupin Pharma Canada Limited — licence 102119, currently licensed, last inspection rating C (2025-07-22).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing LETERMOVIR
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02559323 | LUPIN-LETERMOVIR | LUPIN PHARMA CANADA LIMITED | Tablet | LETERMOVIR 240 MG | Marketed |
| 02469375 | PREVYMIS | MERCK CANADA INC | Tablet | LETERMOVIR 240 MG | Marketed |
| 02469383 | PREVYMIS | MERCK CANADA INC | Tablet | LETERMOVIR 480 MG | Marketed |
| 02469367 | PREVYMIS | MERCK CANADA INC | Solution | LETERMOVIR 20 MG | Marketed |
| 02469405 | PREVYMIS | MERCK CANADA INC | Solution | LETERMOVIR 20 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 37362 | 2026-04-20 | Abbreviated New Drug Submission (ANDS) |
International API supply for LETERMOVIR
10 active FDA Drug Master Files.
Request a quote for LUPIN-LETERMOVIR